Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer
Sign Up to like & getrecommendations! Published in 2021 at "European Thyroid Journal"
DOI: 10.1159/000514182
Abstract: Introduction: Tyrosine kinase inhibitors represent a better treatment in patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC). Lenvatinib is usually well-tolerated, but sometimes, it is associated with serious and even life-threatening side effects. The aim… read more here.
Keywords: organ perforation; patients treated; perforation; thyroid cancer ... See more keywords